ICYMI: AstraZeneca Profit, Revenue Lifted by ...

In a piece written for Bloomberg Businessweek magazine, Daron Acemoglu, Institute Professor of MIT's Department of Economics, muses on whether there is a way to better understand the mind and methodology of US President Donald Trump. Acemoglu writes that "most of the (Trump) admi ...  Show more

Featuring some of our favorite conversations of the week from our daily radio show "Bloomberg Businessweek Daily."Hosted by Carol Massar and Tim StenovecHear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Sirius/ ...  Show more

Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ...

David Faber and Jim Cramer discuss the massive surge for stocks. Multiple reports emerging saying dexamethasone, a widely available drug, can help critically ill coronavirus patients. The treatment reportedly reduced Covid-19 deaths in hospitalized patients by up to one third. ...

David Faber and Jim Cramer began the hour by breaking down another volatile day for the markets, with the major indices coming off their 4th negative session in 5. JPMorgan also raised their odds of a U.S. recession by year end to 35%. A big earnings mover today included Eli L ...

Carl Quintanilla and Jim Cramer focused on shares of Intel tumbling after the chipmaker posted fourth-quarter results that missed expectations -- and warned of a loss in Q1. The anchors reacted to CEO Pat Gelsinger's earnings call comment: "We realize that we stumbled." The Fed's ...  Show more